Mucins (MUC) protect epithelial barriers from environmental insult to maintain homeostasis.
However, their aberrant overexpression and glycosylation in various malignancies facilitate …

The selective permeability of the plasma membrane prohibits most exogenous agents from
gaining cellular access. Since many therapeutics and reporter molecules must be …

The detection of cell-bound proteins that are produced due to aberrant gene expression in
malignant tumors can provide important diagnostic information influencing patient …

The pretargeting strategy has recently emerged in order to overcome the limitations of direct
targeting, mainly in the field of radioimmunotherapy (RIT). This strategy is directly dependent …

In recent years, biotechnologically derived peptide and protein-based drugs have
developed into mainstream therapeutic agents. Peptide and protein drugs now constitute a …

Recombinant antibody fragments, most notably Fab and scFv, have become important tools
in research, diagnostics and therapy. Since different recombinant antibody formats exist, it is …

Monoclonal antibody (mAb) therapy has successfully been introduced as treatment of
several lymphomas and leukemias. However, solid tumors reduce the efficacy of mAb …

Recombinant antibodies, including whole antibodies, antibody fragments, antibody fusion
proteins or conjugates, and more recently also small antibody mimetics, have found …

The anti-cytokeratin (CK) 8 monoclonal antibody (mab) TS1 has been shown to efficiently
bind to CK8 expressed in carcinomas in vivo. The anti-idiotypic antibody of TS1, αTS1, can …

Photodynamic therapy (PDT) is a promising approach for the treatment of superficially
localized tumors. A limitation, however, is the lack of selectivity of the photosensitizers, which …